Free Trial
OTCMKTS:NHNKY

Nihon Kohden 8/2/2024 Earnings Report

Nihon Kohden logo
$12.14 +0.74 (+6.46%)
As of 01:12 PM Eastern

Nihon Kohden EPS Results

Actual EPS
$0.03
Consensus EPS
N/A
Beat/Miss
N/A
One Year Ago EPS
N/A

Nihon Kohden Revenue Results

Actual Revenue
$296.53 million
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Nihon Kohden Announcement Details

Quarter
Time
N/A
Conference Call Date
N/A
Conference Call Time
N/A

Upcoming Earnings

Nihon Kohden's next earnings date is estimated for Thursday, July 31, 2025, based on past reporting schedules.

Conference Call Resources

Nihon Kohden Earnings Headlines

Nihon Kohden (OTCMKTS:NHNKY) Shares Gap Up - Time to Buy?
Banks aren’t ready for this altcoin—are you?
I've never been more confident about a DeFi opportunity. This isn't about complex trading or risky bets. This is about being in the right place at the right time – and I believe that time is now.
Nihon Kohden FY Net Y14.10B Vs Net Y17.03B
Nihon Kohden’s Strategic Share Buyback Plan
See More Nihon Kohden Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Nihon Kohden? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Nihon Kohden and other key companies, straight to your email.

About Nihon Kohden

Nihon Kohden (OTCMKTS:NHNKY) is a Tokyo-based medical electronics company founded in 1951. Specializing in the design, development and manufacture of a wide range of healthcare devices, the company has built a reputation for innovation in patient monitoring, neurological diagnostics and life support equipment. Over its history, Nihon Kohden has introduced numerous industry‐first technologies, including advanced electrocardiography systems and portable defibrillators, to support clinicians in critical care environments.

The company’s primary product portfolio encompasses patient monitors, defibrillators, electroencephalographs (EEG) and electrocardiographs (ECG), as well as in vitro diagnostic instruments such as hematology analyzers and immunoassay systems. Nihon Kohden’s patient monitoring solutions offer real‐time vital signs tracking, while its neurodiagnostic devices provide high‐resolution brainwave analysis for epilepsy and sleep disorder assessments. In vitro diagnostics products deliver automated testing capabilities for clinical laboratories, facilitating rapid and reliable blood cell counts and biomarker detection.

Operating in more than 140 countries, Nihon Kohden maintains a global network of sales, service and distribution centers across North America, Europe, Asia and the Middle East. The company’s international subsidiaries and partnerships enable localized technical support and training for healthcare professionals, ensuring optimal use of its equipment in diverse clinical settings. Manufacturing facilities in Japan and overseas adhere to stringent quality standards, reflecting the company’s commitment to safety and performance.

Guided by a board of directors and executive leadership focused on long‐term growth, Nihon Kohden invests heavily in research and development. The company holds numerous patents in biomedical technology and collaborates with universities, hospitals and research institutes to advance new diagnostic and monitoring solutions. Through ongoing innovation and global outreach, Nihon Kohden aims to enhance patient care and contribute to improvements in healthcare delivery worldwide.

View Nihon Kohden Profile

More Earnings Resources from MarketBeat